JERUSALEM--(BUSINESS WIRE)--Feb. 24, 2014--
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”)
announced today that it has filed its 2013 Annual Report on Form 20-F
with the U.S. Securities and Exchange Commission. The Annual Report can
be found on the company’s website at www.tevapharm.com
as well as on the SEC website at www.sec.gov.
In addition, security holders may request a hard copy of the Annual
Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva
Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by
phone at (215) 591-8912.
About Teva
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical
company, committed to increasing access to high-quality healthcare by
developing, producing and marketing affordable generic drugs as well as
innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world’s leading
generic drug maker, with a global product portfolio of more than 1,000
molecules and a direct presence in approximately 60 countries. Teva’s
branded businesses focus on CNS, oncology, pain, respiratory and women’s
health therapeutic areas as well as biologics. Teva currently employs
approximately 45,000 people around the world and reached $20.3 billion
in net revenues in 2013.
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR Contacts:
United States
Kevin
C. Mannix, (215) 591-8912
or
United States
Ran
Meir, (215) 591-3033
or
Israel
Tomer Amitai, 972
(3) 926-7656
or
PR Contacts:
Israel
Iris Beck
Codner, 972 (3) 926-7687
or
United States
Denise
Bradley, (215) 591-8974